Prestige Healthcare's FY2026 Earnings: Growth & Acquisitions Ahead

Prestige Consumer Healthcare reported a four percent revenue drop in fiscal 2026, with Q4 hit hard by a tough market and production delays. Despite challenges, GI franchises like Dramamine and Hydralyte grew, while womens health brands held market share. Adjusted EPS fell to $4.38, but free cash flow rose slightly. Consumers favored trusted brands, limiting damage. For 2027, Prestige expects one to three percent organic growth, with eye care ramping up in the second half. Pending acquisitions will boost international sales. Over the next three years, they aim for ten percent sales growth, eight percent plus on EPS, and $900 million in free cash flow for debt paydown and value creation. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a4f1b6c79a444aef